Vedanta thinks its live biotherapeutic sourced from clonal cell banking could offer strong prevention against C. difficile infections after antibiotics have cleared an initial infection.

What on earth would make a biotech company change the primary endpoint half way through a Phase III program and not discuss it with the FDA? There are at least two scenarios, neither of them good.

Korean bioventure Genome & Co. is accelerating growth by acquiring US microbiome CDMO List Labs, following on from its purchase of US microbiome therapeutics firm Scioto last year. With its microbiome pipeline reaching milestones as planned, Genome appears on track for its goal of becoming a fully integrated global biopharma concern.

Seattle biotech raised $36m series A in March, now obtains glaucoma and AMD drug candidates along with delivery technology. Alligator, Orion partner on bispecific antibodies for cancer.